Pancreatic enzyme replacement therapy (PERT) for malabsorption in patients with metastatic pancreatic cancer
- PMID: 25164613
- DOI: 10.1136/bmjspcare-2014-000694
Pancreatic enzyme replacement therapy (PERT) for malabsorption in patients with metastatic pancreatic cancer
Abstract
Purpose: The diagnosis of metastatic pancreatic cancer (PC) carries a poor prognosis. PC is associated with weight loss and malabsorption in high rates secondary to pancreatic exocrine insufficiency. UK and USA guidelines exist recommending the empiric use of pancreatic enzyme replacement therapy (PERT) for quality of life in these patients. The aim of this study is to review the use of PERT in patients with metastatic PC referred to a specialist palliative care service.
Methods: Retrospective observational study of patients referred to the service between January 2010 and July 2012 with a diagnosis of PC. Information about PERT use, tumour site and frequency of symptoms was collected.
Results: 129 patients were referred, with a higher number in the eighth decade. Only 21% of this study group were prescribed PERT. Over 70% of patients had symptoms that could be attributable to malabsorption, mainly abdominal pain. Other symptoms such as bloating, wind and steatorrhoea were also common.
Conclusions: Guidelines recommending empiric treatment of PERT in patients with metastatic PC are not currently being utilised.
Keywords: Pharmacology; Supportive care.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Similar articles
-
Impact of the treatment of pancreatic exocrine insufficiency on survival of patients with unresectable pancreatic cancer: a retrospective analysis.BMC Cancer. 2018 May 5;18(1):534. doi: 10.1186/s12885-018-4439-x. BMC Cancer. 2018. PMID: 29728096 Free PMC article.
-
Frequency of Appropriate Use of Pancreatic Enzyme Replacement Therapy and Symptomatic Response in Pancreatic Cancer Patients.Pancreas. 2019 Jul;48(6):780-786. doi: 10.1097/MPA.0000000000001330. Pancreas. 2019. PMID: 31210656 Free PMC article.
-
Exocrine pancreatic insufficiency following esophagectomy.Dis Esophagus. 2013 Aug;26(6):594-7. doi: 10.1111/dote.12004. Epub 2012 Nov 30. Dis Esophagus. 2013. PMID: 23199208
-
CREON (Pancrelipase Delayed-Release Capsules) for the treatment of exocrine pancreatic insufficiency.Adv Ther. 2010 Dec;27(12):895-916. doi: 10.1007/s12325-010-0085-7. Epub 2010 Nov 15. Adv Ther. 2010. PMID: 21086085 Review.
-
Maldigestion from pancreatic exocrine insufficiency.J Gastroenterol Hepatol. 2013 Dec;28 Suppl 4:99-102. doi: 10.1111/jgh.12406. J Gastroenterol Hepatol. 2013. PMID: 24251713 Review.
Cited by 7 articles
-
Pancreatic Enzyme Replacement Therapy: A Concise Review.JOP. 2019;20(5):121-125. Epub 2019 Jul 30. JOP. 2019. PMID: 31736680 Free PMC article.
-
Contribution of pancreatic enzyme replacement therapy to survival and quality of life in patients with pancreatic exocrine insufficiency.World J Gastroenterol. 2019 May 28;25(20):2430-2441. doi: 10.3748/wjg.v25.i20.2430. World J Gastroenterol. 2019. PMID: 31171887 Free PMC article.
-
The effectiveness of pancreatic enzyme replacement therapy for malabsorption in advanced pancreatic cancer, a pilot study.Palliat Care. 2019 Feb 17;12:1178224218825270. doi: 10.1177/1178224218825270. eCollection 2019. Palliat Care. 2019. PMID: 30799929 Free PMC article.
-
Challenges in the management of pancreatic exocrine insufficiency.World J Gastrointest Pharmacol Ther. 2018 Oct 25;9(5):39-46. doi: 10.4292/wjgpt.v9.i5.39. World J Gastrointest Pharmacol Ther. 2018. PMID: 30397535 Free PMC article.
-
Impact of the treatment of pancreatic exocrine insufficiency on survival of patients with unresectable pancreatic cancer: a retrospective analysis.BMC Cancer. 2018 May 5;18(1):534. doi: 10.1186/s12885-018-4439-x. BMC Cancer. 2018. PMID: 29728096 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
-
Full Text Sources
-
Medical